Investor Presentaiton
Transaction Overview
Agreement to
acquire Mirati for:
$58.00
per share in cash
$12.00
non-tradeable CVR for each Mirati
share; converts upon U.S. FDA
acceptance of a new drug application
for MRTX1719 for the treatment of
either locally advanced or metastatic
NSCLC in patients who have received
no more than two prior lines of
systemic therapy
Expected to close by 1H2024, subject to
fulfillment of customary closing
conditions, including approval of Mirati's
stockholders and receipt of required
regulatory approvals.
Differentiated
oncology portfolio:
KRAZATI
(KRASG12C Inhibitor)
MRTX1719
(PRMT5 Inhibitor)
Early clinical pipeline
(Assets include MRTX1133 and
MRTX0902)
KRAZATI:
Best-in-class KRASG12C
inhibitor
Approved
in 2L KRASG12C NSCLC
Expansion potential
in KRASG12C 1L NSCLC, 2L / 3L CRC
and other solid tumors
Creates value
for BMS
IRR exceeds Mirati cost of capital
Maintain strong financial flexibility
enabling prioritizing additional
business development, growing the
dividend, opportunistic share
repurchases
All-cash transaction funded with a
combination of cash and debt
Expect to maintain strong
investment grade credit ratings
Ill Bristol Myers Squibb™
Acquisition of Mirati Strengthens and Diversifies Oncology Portfolio
Not for Product Promotional Use
6View entire presentation